Abstract Number: 1524 • ACR Convergence 2023
The Effectiveness of Nintedanib in Treating Fibrosing Interstitial Lung Disease in Both Scleroderma and Non-scleroderma Patients: A Systematic Review and Meta-analysis
Background/Purpose: Nintedanib, an intracellular inhibitor of tyrosine kinases, has shown promise in clinical trials by inhibiting key processes associated with the advancement of lung fibrosis.…Abstract Number: 2366 • ACR Convergence 2023
Spatial Frequency Domain Imaging as a Novel Method to Quantify Longitudinal Skin Changes in Scleroderma
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by excessive collagen deposition in the skin and internal organs, along with vascular dysfunction. The modified…Abstract Number: 0093 • ACR Convergence 2023
Single Cell RNA-seq and Mass Cytometry Reveal a Cytotoxic CD8 Effector T Cell Population Associated with Interstitial Lung Disease in Systemic Sclerosis Patients
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify features of circulating immune…Abstract Number: 0639 • ACR Convergence 2023
Evaluating Esophageal Dysmotility by Scintigraphy in Systemic Sclerosis: Subsets and Phenotypes
Background/Purpose: Gastrointestinal (GI) dysmotility affects most patients with systemic sclerosis (SSc), and the esophagus is the most commonly affected region. While most SSc patients are…Abstract Number: 0944 • ACR Convergence 2023
Macrophages Regulate Adipocyte Differentiation and Proliferation in Skin Fibrosis
Background/Purpose: Autoimmune systemic sclerosis (SSc) is characterized by inflammation, vasculopathy, and dermal and internal organ fibrosis. A widely-reported but poorly understood aspect of SSc skin…Abstract Number: 1527 • ACR Convergence 2023
Acute Effects of Intravenous Iloprost on Finger Power Doppler Ultrasound in Scleroderma Patients
Background/Purpose: So far few studies explored ultrasound (US) as a tool to assess vascular subcutaneous involvement in patients affected by systemic sclerosis (SSc). We aim…Abstract Number: 2368 • ACR Convergence 2023
Is Skin Disease a Local Manifestation of Systemic Tissue Turnover? Serological Collagen Biomarkers Provide Important Information on Skin Diseases Arising from Mutations in Collagen Genes
Background/Purpose: Collagens are the main constituents of the skin. Genetic mutations in type VI, VII, and XVII collagen cause skin diseases, such as atopic dermatitis,…Abstract Number: 0283 • ACR Convergence 2023
Transcriptomic Profiles in Muscle Biopsies from Systemic Sclerosis Patients with Different Autoantibodies
Background/Purpose: The inflammatory myopathies (IM) include dermatomyositis (DM), antisynthetase syndrome (AS), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), and overlap myositis (OM), in which…Abstract Number: 0641 • ACR Convergence 2023
The Evaluation of Lower Extremities Arterial Disease in Systemic Sclerosis Patients Through Rheumatologist-Vascular Surgeon Multidisciplinary Management: Preliminary Data from an Italian Single Center Study
Background/Purpose: The occurrence of lower limbs macrovascular complications configuring lower extremities arterial disease (LEAD) has been reported in Systemic Sclerosis (SSc) patients. Recently, digital ulcers…Abstract Number: 0945 • ACR Convergence 2023
The Nuclear Receptor TR4 Orchestrates Cytoskeletal Organization in a Gα12/ROCK-dependent Manner to Promote Myofibroblast Differentiation and Tissue Fibrosis in Systemic Sclerosis
Background/Purpose: Members of the superfamily of nuclear receptors have been implicated in inflammatory processes and pathologic tissue remodeling and have emerged as attractive targets for…Abstract Number: 1528 • ACR Convergence 2023
Intravenous or Subcutaneous Immunoglobulins as Potential Treatment for Gastrointestinal, Cutaneous and Vascular Involvement in Systemic Sclerosis: Data from an Italian Cohort of 65 Patients
Background/Purpose: Treatment of systemic sclerosis (SSc) is challenging, and in the last 2 decades there has been an increasing interest for immunoglobulin (Igs) treatment as…Abstract Number: 2369 • ACR Convergence 2023
Investigating Macrophage Heterogeneity in the Esophagus of SSc Patients
Background/Purpose: Systemic sclerosis (SSc) is characterized by an initial inflammatory phase followed by fibrosis. Esophageal dysfunction in SSc is associated with Gastroesophageal Reflux Disease (GERD),…Abstract Number: 0332 • ACR Convergence 2023
Initial Characterization of a Skin Symptom Questionnaire for Patients with Systemic Sclerosis
Background/Purpose: Skin disease is a hallmark of systemic sclerosis (SSc). The modified Rodnan skin score (mRSS) is physician performed measurement that assesses the extent and…Abstract Number: 0642 • ACR Convergence 2023
Clinical Characteristics of Systemic Sclerosis, Systemic Sclerosis Overlap Syndromes and Systemic Sclerosis-mixed Connective Tissue Disease in an Asia-Pacific Cohort- an APLAR Scleroderma Special Interest Group Study
Background/Purpose: Systemic sclerosis (SSc) patients with clinical features of another connective tissue disease (CTD) may have different clinical characteristics from patients with SSc alone. Our…Abstract Number: 0950 • ACR Convergence 2023
KL-6 and IL-18 Levels Are Negatively Correlated with Respiratory Function Tests and ILD Extent Assessed on HRCT in Patients with Systemic Sclerosis-related Interstitial Lung Disease (SSc-ILD)
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Serum biomarkers have been suggested as…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 28
- Next Page »